Research Paper Volume 12, Issue 2 pp 1114—1127

Figure 1. The high expression of Romo1 is associated with the poor prognosis of glioblastoma patients. (A) The mRNA levels of Romo1 in the tumor tissues of glioblastoma patients (n=156) and the healthy brain tissues (n=5) were compared. The mRNA levels were compared between the samples with RNA-Seq data published in TCGA database. (B) The survival curves of the glioblastoma patients with high expression (n=127) and low expression (n=384) of Romo1. The mRNA levels were compared between the samples with mRNA microarray data published in TCGA database. (C) The protein levels of Romo1 in different types of patient-derived immune cells were detected by western blotting. (D) The mRNA levels of Romo1 in different types of patient-derived immune cells were analyzed by RT-qPCR. (E) The tissue sections of the paratumors and tumors from glioblastoma patients were analyzed by immunofluorescence with DAPI, Romo1 and CD11b antibodies. The CD11b positive cells and the Romo1 positive cells were quantified and statistically analyzed from three independent experiments. *, P < 0.05; **, P < 0.01.